In recent years, the use of biologic drugs has greatly changed the therapy of psoriasis and psoriatic arthritis, but they have some adverse effects. In particular, skin lesions induced by anti-tumor necrosis factor (TNF) and anti-interleukin (IL) 12/23 drug (ustekinumab) have been reported with an increased incidence, highlighting the importance of the skin as a major target of the side effects of these drugs. There is a wide spectrum of skin lesions of different morphology and etiology that includes skin lesions directly related to drug administration, the development of cutaneous immune-mediated conditions and cutaneous infections. The aim of this review is to revisit the literature data on inflammatory/infectious skin adverse effects of biologics both anti-TNF-α inhibitors and anti-IL 12/23 antagonists and to report and update our personal data on inflammatory/infectious side effects in patients with psoriasis/psoriatic arthritis treated with biologics.

Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data

RONGIOLETTI, FRANCO;
2014

Abstract

In recent years, the use of biologic drugs has greatly changed the therapy of psoriasis and psoriatic arthritis, but they have some adverse effects. In particular, skin lesions induced by anti-tumor necrosis factor (TNF) and anti-interleukin (IL) 12/23 drug (ustekinumab) have been reported with an increased incidence, highlighting the importance of the skin as a major target of the side effects of these drugs. There is a wide spectrum of skin lesions of different morphology and etiology that includes skin lesions directly related to drug administration, the development of cutaneous immune-mediated conditions and cutaneous infections. The aim of this review is to revisit the literature data on inflammatory/infectious skin adverse effects of biologics both anti-TNF-α inhibitors and anti-IL 12/23 antagonists and to report and update our personal data on inflammatory/infectious side effects in patients with psoriasis/psoriatic arthritis treated with biologics.
Adjuvants, immunologic; Antibodies, monoclonal, Humanized; Arthritis, psoriatic; Humans; Interleukin-12; Psoriasis; Tumor necrosis factor-alpha; Ustekinumab
File in questo prodotto:
File Dimensione Formato  
biologics psoriasis side effects GIDV 2014.pdf

non disponibili

Descrizione: articolo completo
Tipologia: versione editoriale
Dimensione 96.37 kB
Formato Adobe PDF
96.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11584/185192
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 3
social impact